Wednesday, July 8, 2026

Patent intelligence · US

US 9051379

Sp1 polypeptides, modified Sp1 polypeptides and uses thereof

granted A61KA61K38/17A61K47/64A61K47/6929
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 9
Applicant portfolio 11
Patent details — US 9051379
Jurisdiction
US
Status
granted
Grant date
Jun 9, 2015
Expiration
Jun 4, 2035
Applicant
Fulcrum SP Ltd.
Claims
24
CPC classes
A61K, A61K38/17, A61K47/64, A61K47/6929
View on Google Patents ↗

Quick answer

US 9051379 (Sp1 polypeptides, modified Sp1 polypeptides and uses thereof) is held by Fulcrum SP Ltd.. Status: granted. Granted Jun 9, 2015. Expires Jun 4, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Fulcrum SP Ltd.
Grant date
Expiration
Claims
24
CPC classes
A61K, A61K38/17, A61K47/64, A61K47/6929, A61P, A61P43/00

More from Fulcrum SP Ltd.

Related pharmaceutical patents in our USPTO index.

  1. US 12109198

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Fulcrum Therapeutics, Inc. · Expires Oct 3, 2044

    granted
  2. US 11819554

    Compositions and methods for modulating FMR1 expression

    Fulcrum Therapeutics, Inc. · Expires Nov 16, 2043

    granted
  3. US 11590111

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Fulcrum Therapeutics, Inc. · Expires Feb 23, 2043

    granted
  4. US 11479770

    Use of p38 inhibitors to reduce expression of DUX4

    Fulcrum Therapeutics, Inc. · Expires Oct 20, 2042

    granted
  5. US 11291659

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Expires Mar 31, 2042

    granted
  6. US 10973805

    Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

    Fulcrum Therapeutics, Inc. · Expires Apr 8, 2041

    granted
  7. US 10537560

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Expires Jan 16, 2040

    granted
  8. US 10342786

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Expires Jul 4, 2039

    granted

Frequently asked questions

What is US patent 9051379?

US 9051379 (Sp1 polypeptides, modified Sp1 polypeptides and uses thereof) is held by Fulcrum SP Ltd.. Status: granted. Granted Jun 9, 2015. Expires Jun 4, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9051379?

Fulcrum SP Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.

When does US 9051379 expire?

Our index shows an expiration date of Jun 4, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.